OSE Immunotherapeutics (XPAR:OSE) EPS (Basic) : €-1.18 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics EPS (Basic)?

OSE Immunotherapeutics's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was €-0.54. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.18.

OSE Immunotherapeutics's EPS (Diluted) for the six months ended in Dec. 2023 was €-0.54. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.18.

OSE Immunotherapeutics's EPS without NRI for the six months ended in Dec. 2023 was €-0.50. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -1.28.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

OSE Immunotherapeutics EPS (Basic) Historical Data

The historical data trend for OSE Immunotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics EPS (Basic) Chart

OSE Immunotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.31

-1.06

-0.93

-0.96

-1.18

OSE Immunotherapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.29	-0.11	-0.85	-0.64	-0.54

OSE Immunotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

OSE Immunotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-23.003	-	0)	/	19.562
	=	-1.18

OSE Immunotherapeutics's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-11.143	-	0)	/	20.500
	=	-0.54

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.18

OSE Immunotherapeutics (XPAR:OSE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

OSE Immunotherapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

6OP:Germany

Address

22, Boulevard Benoni Goullin, Nantes, FRA, 44200

Website

http://www.ose-immuno.com

OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines